The Efficacy and Safety of Methotrexate versus Interferon in Cutaneous T-cell Lymphomas.

Related Articles

The Efficacy and Safety of Methotrexate versus Interferon in Cutaneous T-cell Lymphomas.

J Dermatolog Treat. 2018 Feb 19;:1-22

Authors: Wain T, Pavli A, Wells J, Fernandez-Peñas P

Abstract
OBJECTIVES: Methotrexate and interferon have been used in the treatment of cutaneous T-cell lymphomas of various subtypes. We review our experience of methotrexate and interferon use in our patients with cutaneous T-cell lymphoma at a tertiary hospital.
MATERIALS AND METHODS: Medical records of patients over four years were reviewed. We describe the dosages, time to response, response rates, side effects, progression rate and reasons for discontinuation.
RESULTS: Response rate was significantly higher in the IFN group than MTX group (86.67% and 47.4% respectively, p = 0.01). Disease progression occurred 57.89% in the MTX group whilst only 26.67% progressed with IFN therapy. Patients taking IFN therapy experienced proportionally more side effects of any type than those undertaking MTX treatment [86.67% vs. 47.37%, Odds ratio 7.22]. However, discontinuation rate in the IFN group (26.67%) was much lower than in the MTX arm (89.47%).
CONCLUSION: The most significant finding of our study was that patients with cutaneous T cell lymphoma treated with IFN had a better response rate and significantly shorter response time compared with those treated with MTX. Additionally, patients had less disease progression on IFN than with MTX regardless of subtype of T cell lymphoma and stage of disease.

PMID: 29455635 [PubMed - as supplied by publisher]

http://ift.tt/2EG6oFI